{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:30:09Z","timestamp":1782930609924,"version":"3.54.5"},"reference-count":32,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Fertility preservation is a key component of cancer care in women of reproductive age, and controlled ovarian stimulation (COS) followed by oocyte\/embryo cryopreservation is considered the standard strategy. Although COS protocols are generally standardized, systemic effects related to different malignancies may interfere with ovarian reserve assessment and influence stimulation planning and counselling. This study aimed to evaluate COS outcomes across different malignancy types in women undergoing fertility preservation. Methods: This retrospective study included 331 oncological patients who underwent COS for fertility preservation at a single referral center between May 2008 and May 2025. Patients were stratified into three groups according to malignancy type: breast cancer, hematological malignancies, and other cancers. Ovarian reserve was assessed using serum anti-M\u00fcllerian hormone (AMH) levels and antral follicle count (AFC). COS outcomes, including stimulation duration, total gonadotropin dose, number of retrieved and mature oocytes, follicular output rate (FORT), and follicle-to-oocyte index (FOI), were compared among groups. Results: Patients with hematological malignancies were significantly younger and showed higher AFC values compared with the other groups, whereas AMH levels did not differ significantly. After adjustment for age and AFC, patients with hematological malignancies showed significantly lower AMH levels compared with breast cancer patients (\u03b2 = \u22120.94 ng\/mL, 95% CI \u22121.40 to \u22120.48, p &lt; 0.001), supporting the presence of a relative AMH\u2013AFC discordance. In unadjusted analyses, gonadotropin requirements were higher in breast cancer patients, whereas the number of retrieved and mature oocytes was higher in patients with hematological malignancies. However, after adjustment for age and AFC, malignancy type was not independently associated with retrieved oocytes, mature oocytes, total gonadotropin dose, or stimulation duration. FORT and FOI were comparable among groups. Conclusions: Malignancy type did not appear to independently impair ovarian responsiveness to stimulation. Patients with hematological malignancies showed preserved stimulation outcomes despite AMH values not being proportionally higher than expected based on their younger age and higher AFC. These findings suggest that AMH should be interpreted with caution in systemic malignancies and that AFC may be particularly useful for tailoring fertility preservation counselling and stimulation strategies when AMH and AFC are discordant.<\/jats:p>","DOI":"10.3390\/jcm15135144","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:50:33Z","timestamp":1782924633000},"page":"5144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Controlled Ovarian Stimulation Outcomes Across Different Malignancies in Women Undergoing Fertility Preservation: The Role of AMH and AFC in Predicting Ovarian Response"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4771-031X","authenticated-orcid":false,"given":"Loris","family":"Marin","sequence":"first","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, University of Padua, Via Giustiniani 3, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Targhetta","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, University of Padua, Via Giustiniani 3, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, University of Padua, Via Giustiniani 3, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ambrosini","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, University of Padua, Via Giustiniani 3, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9428-4363","authenticated-orcid":false,"given":"Alessandra","family":"Andrisani","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, University of Padua, Via Giustiniani 3, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","unstructured":"GBD 2023 Childhood Cancer Collaborators (2026). Global burden of cancer in children and adolescents aged 0\u201319 years, 1990\u20132023: A systematic analysis for the Global Burden of Disease Study 2023. Lancet, 407, 1360\u20131373."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103958","DOI":"10.1016\/j.esmoop.2024.103958","article-title":"Global trends in adolescent and young adult female cancer burden, 1990\u20132021: Insights from the Global Burden of Disease study","volume":"9","author":"Huang","year":"2024","journal-title":"ESMO Open"},{"key":"ref_3","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/17446651.2025.2596680","article-title":"Advances to Fertility Preservation in Patients with Gynecological Cancers","volume":"21","author":"Marin","year":"2026","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.31083\/j.ceog4909206","article-title":"Fertility Preservation in Girls and Women: State of Art and Future Possibilities","volume":"49","author":"Marin","year":"2022","journal-title":"Clin. Exp. Obstet. Gynecol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/00324728.2023.2298678","article-title":"Change in the perceived reproductive age window and delayed fertility in Europe","volume":"79","author":"Lazzari","year":"2025","journal-title":"Popul. Stud."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.fertnstert.2025.07.007","article-title":"Fertility preservation and mental health among cancer patients of reproductive age","volume":"124","author":"Stal","year":"2025","journal-title":"Fertil. Steril."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility Preservation in People With Cancer: ASCO Guideline Update","volume":"43","author":"Su","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE Guideline: Female Fertility Preservation","volume":"2020","author":"Anderson","year":"2020","journal-title":"Hum. Reprod. Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104878","DOI":"10.1016\/j.rbmo.2025.104878","article-title":"Letrozole or tamoxifen co-administration during fertility preservation for patients affected by breast cancer","volume":"51","author":"Lifshitz","year":"2025","journal-title":"Reprod. Biomed. Online"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s10815-023-02882-0","article-title":"Outcomes of Random-Start Letrozole Protocol with PGT-A in Women with Breast Cancer Undergoing Fertility Preservation","volume":"40","author":"Turan","year":"2023","journal-title":"J. Assist. Reprod. Genet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The Role of Cytokines in Classical Hodgkin Lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428199809058383","article-title":"Production and Effects of Interleukin-6 and Other Cytokines in Patients with Non-Hodgkin\u2019s Lymphoma","volume":"29","author":"Kato","year":"1998","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.fertnstert.2016.06.035","article-title":"High Cytokine Expression and Reduced Ovarian Reserve in Patients with Hodgkin Lymphoma or Non-Hodgkin Lymphoma","volume":"106","author":"Paradisi","year":"2016","journal-title":"Fertil. Steril."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10815-024-03050-8","article-title":"Significance of Serum AMH and Antral Follicle Count Discrepancy for the Prediction of Ovarian Stimulation Response in Poseidon Criteria Patients","volume":"41","author":"Hochberg","year":"2024","journal-title":"J. Assist. Reprod. Genet"},{"key":"ref_16","unstructured":"(2024). American Association for Cancer Research AACR Cancer Progress Report 2024, American Association for Cancer Research."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.fertnstert.2007.10.080","article-title":"A New Approach to Ovarian Reserve Testing","volume":"90","author":"Sun","year":"2008","journal-title":"Fertil. Steril."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.fertnstert.2010.07.1069","article-title":"Age-Specific Nomogram for the Decline in Antral Follicle Count throughout the Reproductive Period","volume":"95","author":"Spada","year":"2011","journal-title":"Fertil. Steril."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kotlyar, A.M., and Seifer, D.B. (2020). Ethnicity\/Race and Age-Specific Variations of Serum AMH in Women\u2014A Review. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.593216"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1210\/clinem\/dgaa513","article-title":"Anti-M\u00fcllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function","volume":"105","author":"Moolhuijsen","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.fertnstert.2012.04.021","article-title":"Reduced Pretreatment Ovarian Reserve in Premenopausal Female Patients with Hodgkin Lymphoma or Non-Hodgkin-Lymphoma--Evaluation by Using Antim\u00fcllerian Hormone and Retrieved Oocytes","volume":"98","author":"Lawrenz","year":"2012","journal-title":"Fertil. Steril."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10815-016-0689-1","article-title":"Female Patients with Lymphoma Demonstrate Diminished Ovarian Reserve Even before Initiation of Chemotherapy When Compared with Healthy Controls and Patients with Other Malignancies","volume":"33","author":"Lekovich","year":"2016","journal-title":"J. Assist. Reprod. Genet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10549-012-2361-5","article-title":"Impact of Breast Cancer on Anti-Mullerian Hormone Levels in Young Women","volume":"137","author":"Su","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"104109","DOI":"10.1016\/j.rbmo.2024.104109","article-title":"Effect of Breast Cancer Prognostic Factors on Ovarian Reserve and Response in Fertility Preservation","volume":"49","author":"Grynberg","year":"2024","journal-title":"Reprod. Biomed. Online"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.fertnstert.2018.10.018","article-title":"Serum Antim\u00fcllerian Hormone Is Associated with the Number of Oocytes Matured in Vitro and with Primordial Follicle Density in Candidates for Fertility Preservation","volume":"111","author":"Sermondade","year":"2019","journal-title":"Fertil. Steril."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40738-018-0048-2","article-title":"Responses to Fertility Treatment among Patients with Cancer: A Retrospective Cohort Study","volume":"4","author":"Dolinko","year":"2018","journal-title":"Fertil. Res. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Anderson, R.A., and Su, H.I. (2020). The Clinical Value and Interpretation of Anti-M\u00fcllerian Hormone in Women With Cancer. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.574263"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/humrep\/det442","article-title":"Decreased Serum Anti-M\u00fcllerian Hormone Levels in Girls with Newly Diagnosed Cancer","volume":"29","author":"Pluijm","year":"2014","journal-title":"Hum. Reprod."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Caringella, A.M., Stanziano, A., Cantatore, C., Vitti, A., Cortone, A., D\u2019Amato, A., Tinelli, R., Aquino, C.I., Libretti, A., and D\u2019Amato, G. (2025). Does the Type of Cancer Influence Anti-M\u00fcllerian Hormone Levels in Women of Reproductive Age? A Cross-Sectional Study. Biomedicines, 13.","DOI":"10.3390\/biomedicines13102542"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Alviggi, C., Conforti, A., Esteves, S.C., Vallone, R., Venturella, R., Staiano, S., Castaldo, E., Andersen, C.Y., and De Placido, G. (2018). Understanding Ovarian Hypo-Response to Exogenous Gonadotropin in Ovarian Stimulation and Its New Proposed Marker-The Follicle-To-Oocyte (FOI) Index. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00589"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Grynberg, M., and Labrosse, J. (2019). Understanding Follicular Output Rate (FORT) and Its Implications for POSEIDON Criteria. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00246"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101815","DOI":"10.1016\/j.jogoh.2020.101815","article-title":"Which Is the Optimal Timing for Starting Chemoprotection with Gonadotropin-Releasing Hormone Agonists after Oocyte Cryopreservation? Reflections on a Critical Case of Ovarian Hyperstimulation Syndrome","volume":"50","author":"Marin","year":"2021","journal-title":"J. Gynecol. Obstet. Hum. Reprod."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:43:01Z","timestamp":1782927781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":32,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135144"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135144","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}